In the CheckMate-067 study in patients with metastatic melanoma, patients had improved OS and PFS with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab alone regardless of BRAF mutation status, tumor PD-L1 expression and lactate dehydrogenase (LDH) status [39]. This evidence concerns the gene CD274 and neoplasm.